Company Update

August 31, 2016

Jubilant Life Sciences (JUBLIF)

Rating matrix
Rating
Target
Target Period
Potential Upside

:
:
:
:

Buy
| 635
15-18 months
18%

Waning debt concerns +FCF generation = rerating

600

Change in methodology from EV/EBITDA to PE as profitability improves

After taking a re-look at an improved leverage situation (a legacy issue for
the company in the last five years) we have critically evaluated our earlier
methodology of applying EV/EBITDA gauge for valuation. We believe it is
the right time to change the same to PE gauge as the debt component in
EV has come down substantially as reflected in Exhibit 2, besides waning
debt stress and improved business mix (hence EBITDA margins). The
situation is likely to improve further in FY16-19E. Accordingly, we arrive at
our new target price of | 635 (from | 420 earlier) based on 10x FY19E EPS
of | 63.5. We still value Jubilant at a substantial discount to peer pharma
companies due to the blended business model (47% of revenues from
commoditised LSI segment) besides a volatile past. However, we do not
rule out a further re-rating in the stock.
Debt no more a fear factor
In its pursuit of building capacity and creating multiple revenue heads the
debt situation had got complicated over the years. As most debt had
been US$ denominated, the sharp rupee depreciation has worsened the
debt situation further. After hitting a trough in FY15, things have started to
change especially in FY16 wherein the company registered its best ever
EBITDA margins in the last 10 years. With an improvement in operational
performance, the free cash flow (FCF) situation has improved markedly.
While the net D/E ratio improved to 1.4x from 1.8x in FY15, the
debt/EBITDA has improved to 3.5x from 7.0x. As the capex cycle
moderates in the medium term, the company expects to utilise maximum
FCF for debt repayment. We expect the net D/E ratio to further go down
to 0.4x by FY19E from 1.4x in FY16 and debt/EBITDA ratio to 1.3x from
3.5x in FY16.
Improvement in sentiment resembles Aurobindo story of FY12-15
By FY12, the debt stress scenario in both Jubilant and Aurobindo was
almost identical with debt/ EV ratios at 60% and 50%, respectively.
Aurobindo registered robust growth in FY12-15 backed by an improved
operational performances and FCF generation. Note that the debt level
kept on increasing during this period. The stock galloped during this
period purely on operational performance (Exhibit 6 and 7). Although an
apple to apple comparison may not be possible (due to lower cost of debt
and robust US franchisee in Aurobindos case) we believe a similar
operational performance story is panning out in Jubilants case despite an
increase in the debt level.

400

Exhibit 1: Net debt to equity (x) and debt/EBITDA (x) trend

Whats Changed?
Target
EPS FY17E
EPS FY18E
EPS FY19E
Rating

Changed from | 420 to | 635

Unchanged
Unchanged
Introducing at | 63.5
Unchanged

Key Financials
(| crore)
Revenues
EBITDA
Net Profit
EPS (|)
Adjusted EPS (|)

FY16
5802.3
1277.8
431.5
27.1
26.0

FY17E
5970.6
1487.7
659.8
41.4
41.4

FY18E
6561.1
1689.7
840.3
52.7
52.7

FY19E
7211.5
1873.4
1011.2
63.5
63.5

FY16
19.8
23.4
10.0
2.9
14.2
12.0

FY17E
13.0
15.3
8.1
2.4
18.8
15.1

FY18E
10.2
12.0
6.7
2.0
19.6
17.0

FY19E
8.5
10.0
5.6
1.6
19.2
18.4

Valuation summary
PE (x)
Target P/E (Diluted)
Tar. EV/EBITDA (x)
Price to book (x)
RoNW (%)
RoCE (%)

Stock data
Amount
| 8556 crore
| 3814 crore
| 334 crore
| 12036 crore
553/261
| 15.9 crore
|1

Particular
Market Capitalisation
Debt (FY16)
Cash (FY16)
EV
52 week H/L
Equity capital
Face value

Price Chart
16000

1000

12000

800

8000
4000

200

0
Jul-16

Jan-16

Jul-15

Jan-15

Jul-14

Jan-14

Jul-13

Jan-13

Jul-12

Jan-12

Jul-11

CNX Pharma

| 537

Alembic Pharma

Research Analyst
Siddhant Khandekar
[email protected]
Mitesh Shah
[email protected]

8.0
7.0

7.1

7.0

6.0
5.0

4.4

4.0
3.0
2.0
1.0

3.7

3.5
2.6

1.3

1.5

1.4

1.8

1.5

1.4

1.0

0.0
FY11

FY12

FY13

FY14

FY15

Net Debt / Equity

Source: Company, ICICIdirect.com Research

ICICI Securities Ltd | Retail Equity Research

4.4

FY16

FY17E

Debt / EBITDA

1.8
0.7
FY18E

1.3
0.4
FY19E

Exhibit 2: Improvement in debt/EV (%)

80.0
70.0
60.0
50.0
40.0
30.0
20.0
10.0
-

Exhibit 3: Expects to generate ~| 2500 crore of FCF in next three years

1,500.0

71.3

68.2

61.8

56.7

70.2

787.7 754.8

1,000.0
500.0

41.8
31.7

27.4

38.1

17.4

22.9

(500.0)
(1,000.0)

FY11 FY12 FY13 FY14 FY15 FY16 FY17E FY18E FY19E

(92.9)
(463.6)
(949.0)

(1,500.0)

Free Cash Flow (| cr)

Debt/EV

Source: Company, ICICIdirect.com Research

Source: Company, ICICIdirect.com, Research

Exhibit 4: Improvement in return ratios (%)

Exhibit 5: Margins performance

25.0

30.0

20.0

10.0
5.0

15.6
12.5

10.2

15.1
11.5

14.2
12.0

12.3
9.7

6.1

18.8
15.1

19.6
17.0

19.2
18.4

25.0
15.0
5.0

FY11

FY12

FY13

FY14

-0.4
FY15 FY16 FY17E FY18E FY19E
RoCE

ROE

Source: Company, ICICIdirect.com Research

ICICI Securities Ltd | Retail Equity Research

20.3

20.0
10.0

5.8

0.0
-5.0

60.0

FY11 FY12 FY13 FY14 FY15 FY16 FY17E FY18E FY19E

15.0

925.0

20.0

16.1
7.9

8.4

22.0

FY11

FY12

FY13

26.0

FY14

11.0

12.8

14.0

7.1

5.6

0.0
-5.0

25.8

17.4
11.8

7.3

24.9

-0.2
FY15 FY16 FY17E FY18E FY19E

EBITDA margins (%)

PAT margins (%)

Source: Company, ICICIdirect.com, Research

Page 2

Exhibit 7: Aurobindo stock price in FY 10-15

1.8
1.0

1.3

1.7
0.9

0.0
FY10

FY11

FY12

FY13

Debt / Equity

FY14

FY15

Aurobindo Stock Price (|)

Debt / EBITDA

Source: Company, ICICIdirect.com Research

Source: Company, ICICIdirect.com, Research

Exhibit 8: Jubilants leverage ratios in FY12-16

Exhibit 9: Jubilant stock price from FY12 till date

600
7.0

Debt / Equity

ICICI Securities Ltd | Retail Equity Research

Aug-16

Apr-16

Dec-15

Apr-15

Series1

Debt / EBITDA

Source: Company, ICICIdirect.com Research

Dec-14

FY16

Aug-14

FY15

100
0
Apr-14

FY14

1.6

Dec-13

FY13

2.0

300
200

Aug-13

FY12

1.7

1.5

3.5

Apr-13

1.6

4.4

3.7

Dec-12

4.4

500
400

Aug-12

8.0
7.0
6.0
5.0
4.0
3.0
2.0
1.0
0.0

Apr-15

1.3

Oct-14

1.0

Apr-14

1.2

Oct-13

2.5

Aug-15

1.0

2.6

Apr-13

2.0

3.9

Oct-12

3.0

Apr-12

4.0

Oct-11

5.0

700.0
600.0
500.0
400.0
300.0
200.0
100.0
0.0
Apr-11

5.1

Oct-10

6.0

Apr-10

Exhibit 6: Aurobindo Pharmas leverage ratios in FY10-15

Source: Company, ICICIdirect.com, Research

Page 3

Financial summary
Profit and loss statement

| Crore

(Year-end March)
FY16
Revenues
5,802.3
Growth (%)
-0.4
Raw Material Expenses
2,126.3
Employee Expenses
1,126.7
Selling & Admin expenses
904.8
Power cost
366.7
Total Operating Expenditure
4,524.5
EBITDA
1,277.8
Growth (%)
85.4
Depreciation
346.0
Interest
378.6
Other Income
13.6
PBT before EO
566.9
Less: Exceptional Items
-17.5
Total Tax
152.9
Minority Interest
0.0
PAT
431.5
Growth (%)
LP
EPS
27.1
Adjusted PAT
414.0
EPS (Adjusted)
26.0
Source: Company, ICICIdirect.com Research

FY17E
5,970.6
2.9
1,952.2
1,251.6
887.0
392.1
4,482.9
1,487.7
16.4
314.6
317.3
14.8
870.6
-0.1
210.8
0.0
659.8
52.9
41.4
659.7
41.4

FY18E
6,561.1
9.9
2,145.3
1,345.0
932.1
449.0
4,871.4
1,689.7
13.6
341.7
255.3
13.0
1,105.6
0.0
265.3
0.0
840.3
27.3
52.7
840.3
52.7

FY17E
15.9
3,497.6
3,513.5
3,814.0
358.6
0.0
163.2
7,849.2
5,559.4
2,368.2
3,191.2
145.1
3,336.3
2,434.0
36.1
1,256.1
835.5
408.4
334.1
63.5
2,897.6
715.6
209.4
339.4
1,264.4
1,633.3
0.0
409.5
7,849.2

FY18E
15.9
4,281.9
4,297.9
3,114.0
398.4
0.0
175.2
7,985.4
5,859.4
2,596.7
3,262.7
145.1
3,407.8
2,420.8
36.1
1,375.9
915.2
408.4
302.9
63.5
3,065.9
783.8
209.4
443.4
1,436.6
1,629.3
0.0
491.4
7,985.4

Balance sheet
(Year-end March)
Equity Capital
Reserve and Surplus
Total Shareholders funds
Total Debt
Deferred Tax Liability
Minority Interest
Other Non CL & LT Provisions
Total Liabilities
Gross Block - Fixed Assets
Accumulated Depreciation
Net Block
Capital WIP
Total Fixed Assets
Total Intangible Assets
Investments
Inventory
Debtors
Loans and Advances
Cash
Other current Assets
Total Current Assets
Creditors
Provisions
Other Current Liabilities
Total Current Liabilities
Net Current Assets
Deferred Tax Assets
LT L & A, Other Non CA
Application of Funds

FY19E
7,211.5
9.9
2,346.2
1,478.4
1,020.0
493.5
5,338.0
1,873.4
10.9
359.3
197.9
14.2
1,330.5
0.0
319.3
0.0
1,011.2
20.3
63.5
1,011.2
63.5

| Crore
FY16
15.9
2,893.6
2,909.6
4,514.0
326.9
0.0
152.1
7,902.6
5,259.4
2,157.8
3,101.7
145.1
3,246.7
2,438.2
36.1
1,216.1
929.7
362.6
344.5
48.5
2,901.3
599.6
209.4
235.4
1,044.5
1,856.9
0.0
324.6
7,902.6

Source: Company, ICICIdirect.com Research

ICICI Securities Ltd | Retail Equity Research

FY19E
15.9
5,237.2
5,253.1
2,414.0
446.3
0.0
188.2
8,301.6
6,159.4
2,836.9
3,322.5
145.1
3,467.6
2,401.8
36.1
1,512.3
1,005.9
408.4
434.6
63.5
3,424.7
861.5
209.4
547.4
1,618.3
1,806.4
0.0
589.7
8,301.6

Cash flow statement

(Year-end March)
Profit/(Loss) after taxation
Add: Depreciation
(Inc)/dec in Current Assets
Inc/(dec) in CL and Provisions
CF from operating activities
(Purchase)/Sale of FA
Deferred Tax Liability
Minority Interest
Investments
Other Investing Activities
CF from investing activities
Inc/(Dec) in Equity Capital
Proceeds/(Repayment) of/from Lo
Dividend & Dividend tax
Others
CF from financing activities

| Crore
FY16
431.5
346.0
-223.3
2.5
556.7
-496.7
88.9
0.0
3.4
-96.8
-501.3
0.0
397.8
-57.5
(97.2)
243.1

FY17E
659.8
314.6
-6.7
219.9
1,187.7
-400.0
31.6
0.0
0.0
41.4
-327.0
0.0
-277.8
-55.9
54.2
-279.6

FY18E
840.3
341.7
-199.5
172.2
1,154.8
-400.0
39.8
0.0
0.0
-82.0
-442.2
0.0
-700.0
-55.9
-755.9

FY19E
1,011.2
359.3
-227.1
181.7
1,325.0
-400.0
47.9
0.0
0.0
-78.0
-430.1
0.0
-700.0
-55.9
-755.9

Net Cash flow

298.5
Opening Cash
394.3
Closing Cash
692.8
Free Cash Flow
60.0
Source: Company, ICICIdirect.com Research

581.2
344.5
925.7
787.7

-43.3
334.1
290.8
754.8

139.0
302.9
441.9
925.0

FY16

FY17E

FY18E

FY19E

27.1
26.0
182.6
3.6
21.6

41.4
41.4
220.6
3.5
21.0

52.7
52.7
269.8
3.5
19.0

63.5
63.5
329.8
3.5
27.3

63.4
22.0
7.1
76.5
58.5
37.7
0.7
43.6

67.3
24.9
11.0
76.8
51.1
43.7
0.8
79.8

67.3
25.8
12.8
76.5
50.9
43.6
0.8
68.3

67.5
26.0
14.0
76.5
50.9
43.6
0.9
70.7

14.2
12.0
12.3

18.8
15.1
15.6

19.6
17.0
17.5

19.2
18.4
19.2

19.8
10.0
2.2
1.5
2.9

13.0
8.1
2.0
1.4
2.4

10.2
6.7
1.7
1.3
2.0

8.5
5.6
1.5
1.2
1.6

1.6
3.5
2.4

1.1
2.6
2.0

0.7
1.8
1.9

0.5
1.3
1.8

Key ratios
(Year-end March)
Per share data (|)
Reported EPS
Adjusted EPS
BV per share
Dividend per share
Cash Per Share
Operating Ratios (%)
Gross Profit Margins
EBITDA Margins
PAT Margins
Inventory days
Debtor days
Creditor days
Asset Turnover
EBITDA conversion Rate
Return Ratios (%)
RoE
RoCE
RoIC
Valuation Ratios (x)
P/E
EV / EBITDA
EV / Net Sales
Market Cap / Sales
Price to Book Value
Solvency Ratios
Debt / Equity
Debt / EBITDA
Current Ratio

Source: Company, ICICIdirect.com Research

Page 4

RATING RATIONALE

ICICIdirect.com endeavours to provide objective opinions and recommendations. ICICIdirect.com assigns

ratings to its stocks according to their notional target price vs. current market price and then categorises them
as Strong Buy, Buy, Hold and Sell. The performance horizon is two years unless specified and the notional
target price is defined as the analysts' valuation for a stock.
Strong Buy: >15%/20% for large caps/midcaps, respectively, with high conviction;
Buy: >10%/15% for large caps/midcaps, respectively;
Hold: Up to +/-10%;
Sell: -10% or more;

Pankaj Pandey

Head Research

[email protected]

ICICIdirect.com Research Desk,

ICICI Securities Limited,
1st Floor, Akruti Trade Centre,
Road No 7, MIDC,
Andheri (East)
Mumbai 400 093
[email protected]

ICICI Securities Ltd | Retail Equity Research

Page 5

ANALYST CERTIFICATION
We /I, Siddhant Khandekar, CA INTER and Mitesh Shah, MS (finance) Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report
accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s)
in this report.

Terms & conditions and other disclosures:

ICICI Securities Limited is a SEBI registered Research Analyst having registration no. INH000000990. ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia,
engaged in the business of stock brokering and distribution of financial products. ICICI Securities is a wholly-owned subsidiary of ICICI Bank which is Indias largest private sector bank and has its various
subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. (associates), the details in respect of which are available
on www.icicibank.com.
ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and
other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities generally prohibits its analysts, persons reporting to analysts and their
relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.
The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant
solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior
written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also,
there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and
such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other
circumstances.
This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This
report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial
instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their
receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances.
The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial
positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The
value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind
arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before
investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to
change without notice.
ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in
the past twelve months.
ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in
respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.
ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in
the report in the past twelve months.
ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its analysts did not receive any compensation or
other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts have any material
conflict of interest at the time of publication of this report.
It is confirmed that Siddhant Khandekar, CA INTER and Mitesh Shah, MS (finance), Research Analysts of this report have not received any compensation from the companies mentioned in the report in the
preceding twelve months.
Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.
ICICI Securities or its subsidiaries collectively or Research Analysts do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the
publication of the research report.
Since associates of ICICI Securities are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject
company/companies mentioned in this report.
It is confirmed that Siddhant Khandekar, CA INTER and Mitesh Shah, MS (finance), Research Analysts do not serve as an officer, director or employee of the companies mentioned in the report.
ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.
Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.
We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.
This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution,
publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities
described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to
observe such restriction.

ICICI Securities Ltd | Retail Equity Research

Page 6